Sarepta Therapeutics, Inc. (NASDAQ:SRPT)‘s stock had its “overweight” rating reiterated by stock analysts at Piper Jaffray Companies in a research note issued on Thursday. They presently have a $55.00 price objective on the biotechnology company’s stock, up from their previous price objective of $50.00. Piper Jaffray Companies’ price objective points to a potential upside of 21.20% from the stock’s current price.

A number of other analysts have also recently weighed in on SRPT. Needham & Company LLC reissued a “buy” rating and issued a $75.00 price objective on shares of Sarepta Therapeutics in a research report on Wednesday. Credit Suisse Group lifted their price target on Sarepta Therapeutics from $5.65 to $81.00 and gave the stock an “outperform” rating in a research report on Thursday. Robert W. Baird reaffirmed an “outperform” rating and set a $101.00 price target on shares of Sarepta Therapeutics in a research report on Wednesday. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and set a $76.00 price target on shares of Sarepta Therapeutics in a research report on Thursday. Finally, Barclays PLC assumed coverage on Sarepta Therapeutics in a research report on Wednesday. They set an “equal weight” rating and a $46.00 price target for the company. Nine research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $62.31.

Sarepta Therapeutics (NASDAQ:SRPT) traded down 2.89% during midday trading on Thursday, reaching $45.38. The company’s stock had a trading volume of 3,787,888 shares. The firm has a 50 day moving average price of $38.96 and a 200-day moving average price of $34.02. The company’s market cap is $2.92 billion. Sarepta Therapeutics has a 12-month low of $25.47 and a 12-month high of $63.73.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.92) by $0.46. The business had revenue of $35.01 million during the quarter, compared to analyst estimates of $22.52 million. The firm’s revenue for the quarter was up 350000.0% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.19) EPS. On average, equities research analysts predict that Sarepta Therapeutics will post ($1.17) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Sarepta Therapeutics, Inc. (SRPT) Stock Rating Reaffirmed by Piper Jaffray Companies” was first posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/09/07/sarepta-therapeutics-inc-srpt-stock-rating-reaffirmed-by-piper-jaffray-companies.html.

In related news, SVP Alexander Cumbo sold 5,918 shares of Sarepta Therapeutics stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $41.00, for a total value of $242,638.00. Following the completion of the transaction, the senior vice president now owns 22,793 shares in the company, valued at approximately $934,513. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Edward M. Md Kaye sold 10,000 shares of Sarepta Therapeutics stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $41.00, for a total value of $410,000.00. Following the completion of the transaction, the director now owns 62,471 shares of the company’s stock, valued at approximately $2,561,311. The disclosure for this sale can be found here. In the last 90 days, insiders sold 78,056 shares of company stock valued at $3,224,208. 9.60% of the stock is owned by company insiders.

A number of hedge funds have recently bought and sold shares of the stock. BlackRock Inc. boosted its holdings in Sarepta Therapeutics by 4,403.1% in the 1st quarter. BlackRock Inc. now owns 5,292,729 shares of the biotechnology company’s stock worth $156,664,000 after buying an additional 5,175,193 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Sarepta Therapeutics by 4.0% in the 2nd quarter. Vanguard Group Inc. now owns 4,259,029 shares of the biotechnology company’s stock worth $143,572,000 after buying an additional 162,543 shares during the last quarter. State Street Corp boosted its holdings in Sarepta Therapeutics by 21.2% in the 1st quarter. State Street Corp now owns 3,197,127 shares of the biotechnology company’s stock worth $94,641,000 after buying an additional 559,342 shares during the last quarter. HealthCor Management L.P. boosted its holdings in Sarepta Therapeutics by 31.1% in the 2nd quarter. HealthCor Management L.P. now owns 2,031,890 shares of the biotechnology company’s stock worth $68,495,000 after buying an additional 481,890 shares during the last quarter. Finally, Camber Capital Management LLC acquired a new stake in Sarepta Therapeutics in the 1st quarter worth about $39,960,000. Institutional investors own 65.43% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.